Blueprint Medicines Corporation

88.69
-1.04 (-1.16%)
At close: Mar 28, 2025, 3:59 PM
88.72
0.03%
Pre-market: Mar 31, 2025, 05:06 AM EDT

Company Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.

The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.

In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.

It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F.

Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd.

The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.

Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Corporation
Blueprint Medicines Corporation logo
Country United States
IPO Date Apr 30, 2015
Industry Biotechnology
Sector Healthcare
Employees 649
CEO Kathryn Haviland M.B.A.

Contact Details

Address:
45 Sidney Street
Cambridge, Massachusetts
United States
Website https://www.blueprintmedicines.com

Stock Details

Ticker Symbol BPMC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001597264
CUSIP Number 09627Y109
ISIN Number US09627Y1091
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Kathryn Haviland M.B.A. President, Chief Executive Officer & Director
Christina Rossi M.B.A. Chief Operating Officer
Debra Durso-Bumpus Chief People Officer
Michael Landsittel CPA Chief Financial Officer
Alexis A. Borisy A.M. Co-Founder & Director
Ariel Hurley Senior Vice President, Finance & Principal Accounting Officer
Dr. Fouad Namouni M.D. President of Research & Development
Dr. Percy H. Carter M.B.A., Ph.D. Chief Scientific Officer
Jenna Cohen Senior Director & Head of Investor Relations
Tracey L. McCain Esq. Executive Vice President, Chief Legal & Compliance Officer and Secretary

Latest SEC Filings

Date Type Title
Mar 26, 2025 4 Filing
Mar 17, 2025 4 Filing
Mar 14, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing
Mar 07, 2025 4 Filing